Whitebox Advisors’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Whitebox Advisors’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-115,000	Closed	-$1.16M	–	757
2022 Q4	$1.16M	Buy	+115,000	New	+$1.15M	0.03%	250
2022 Q2	–	Sell	-115,000	Closed	-$1.13M	–	1001
2022 Q1	$1.13M	Sell	115,000 -10,000	-8%	-$98.5K	0.02%	303
2021 Q4	$1.23M	Hold	125,000	–	–	0.03%	274
2021 Q3	$1.22M	Hold	125,000	–	–	0.03%	233
2021 Q2	$1.21M	Hold	125,000	–	–	0.02%	201
2021 Q1	$1.21M	Buy	+125,000	New	+$1.21M	0.04%	155

Whitebox Advisors's BIOT Position: Q1 2023 in Review

Whitebox Advisors sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 115,000 shares — an estimated $1.16M sold.

Whitebox Advisors first reported a position in BIOT in Q1 2021 and held it in 6 quarters. The position peaked at $1.23M in Q4 2021. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Whitebox Advisors reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Whitebox Advisors sold 115,000 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $1.16M.
Whitebox Advisors first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2021 and held it in 6 quarters.
Whitebox Advisors's Biotech Acquisition Company Class A Ordinary Shares position peaked at $1.23M in Q4 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Whitebox Advisors's 13F filing for Q1 2023, filed 15 May 2023.